{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:55:58Z","timestamp":1773741358279,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jbspin.2023.105625","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T19:52:45Z","timestamp":1690228365000},"page":"105625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-6512","authenticated-orcid":false,"given":"Patrick","family":"Yousif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-2835","authenticated-orcid":false,"given":"Vicky","family":"Nahra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-5619","authenticated-orcid":false,"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2023.105625_bib0325","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/art.1780210603","article-title":"Seronegative polyarthritis: a unified concept","volume":"21","author":"Wright","year":"1978","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105625_bib0330","doi-asserted-by":"crossref","first-page":"e002872","DOI":"10.1136\/rmdopen-2022-002872","article-title":"Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes","volume":"9","author":"Proft","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105625_bib0335","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/RHU.0000000000001815","article-title":"Psoriatic spondylitis: a disease manifestation in debate: evidences to know for the clinical rheumatologist","volume":"28","author":"Zeidler","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0340","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105625_bib0345","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13244-010-0061-4","article-title":"Imaging the spine in arthritis-a pictorial review","volume":"2","author":"Jurik","year":"2011","journal-title":"Insights Imaging"},{"key":"10.1016\/j.jbspin.2023.105625_bib0350","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.57.3.135","article-title":"Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?","volume":"57","author":"Helliwell","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0355","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.rdc.2020.01.009","article-title":"Axial psoriatic arthritis: a distinct clinical entity in search of a definition","volume":"46","author":"Michelena","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2023.105625_bib0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","article-title":"Axial disease in psoriatic arthritis","volume":"9","author":"Gladman","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2023.105625_bib0365","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.3899\/jrheum.090412","article-title":"Axial psoriatic arthritis: update on a longterm prospective study","volume":"36","author":"Chandran","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0370","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0375","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/BOR.0000000000000609","article-title":"Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?","volume":"31","author":"Chandran","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0380","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-021-00999-8","article-title":"Axial Psoriatic Arthritis","volume":"23","author":"Gladman","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2023.105625_bib0385","doi-asserted-by":"crossref","first-page":"105409","DOI":"10.1016\/j.jbspin.2022.105409","article-title":"Axial psoriatic arthritis: new entity or clinical form only?","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105625_bib0390","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.3346\/jkms.2022.37.e253","article-title":"Clinical characteristics of patients with psoriatic spondylitis versus those with ankylosing spondylitis: features at baseline before biologic therapy","volume":"37","author":"Kim","year":"2022","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jbspin.2023.105625_bib0395","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/ard.47.5.386","article-title":"Psoriatic spondyloarthropathy: a long term prospective study","volume":"47","author":"Hanly","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0400","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.semarthrit.2021.04.018","article-title":"Unveiling axial involvement in psoriatic arthritis: an ancillary analysis of the ASAS-perSpA study","volume":"51","author":"Benavent","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105625_bib0405","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1136\/ard-2022-222537","article-title":"Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis","volume":"81","author":"Kwok","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0410","doi-asserted-by":"crossref","first-page":"e002513","DOI":"10.1136\/rmdopen-2022-002513","article-title":"Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry","volume":"8","author":"Michelena","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105625_bib0415","doi-asserted-by":"crossref","first-page":"e2837","DOI":"10.1136\/rmdopen-2022-002837","article-title":"Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA","volume":"9","author":"Regierer","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105625_bib0420","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/1756-185X.14537","article-title":"Similarities and differences between axial spondyloarthritis and axial psoriatic arthritis","volume":"26","author":"Wang","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0425","doi-asserted-by":"crossref","first-page":"142","DOI":"10.31138\/mjr.33.1.142","article-title":"Axial disease in psoriatic arthritis: how can we define it, and does it have an impact on treatment?","volume":"33","author":"Lopez-Medina","year":"2022","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0430","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.171094","article-title":"Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the corrona psoriatic arthritis\/spondyloarthritis registry","volume":"45","author":"Mease","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0435","doi-asserted-by":"crossref","first-page":"e002956","DOI":"10.1136\/rmdopen-2022-002956","article-title":"Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry","volume":"9","author":"Ciurea","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105625_bib0440","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3899\/jrheum.091059","article-title":"Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis","volume":"37","author":"Chandran","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0445","unstructured":"Poddubnyy D, Baraliakos X, et al. Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis."},{"key":"10.1016\/j.jbspin.2023.105625_bib0450","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s12325-023-02475-4","article-title":"Genetic and molecular distinctions between axial psoriatic arthritis and radiographic axial spondyloarthritis: post hoc analyses from four phase 3 clinical trials","volume":"40","author":"Kavanaugh","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jbspin.2023.105625_bib0455","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0460","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0465","doi-asserted-by":"crossref","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","article-title":"IL-23 and axial disease: do they come together?","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0470","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/rheumatology\/keaa437","article-title":"Axial spondyloarthritis: coming of age","volume":"59","author":"Marzo-Ortega","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0475","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2023.105625_bib0480","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23-dependent gamma\/delta T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0485","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis gammadeltaT-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0490","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0495","doi-asserted-by":"crossref","first-page":"614255","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0500","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","article-title":"The many faces of psoriatic arthritis: their genetic determinism","volume":"59","author":"Winchester","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0505","first-page":"270","article-title":"Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis","volume":"35","author":"Haroon","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0510","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/ard.51.1.73","article-title":"The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study","volume":"51","author":"Salvarani","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0515","doi-asserted-by":"crossref","first-page":"e002994","DOI":"10.1136\/rmdopen-2023-002994","article-title":"Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts","volume":"9","author":"de Hooge","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105625_bib0520","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40265-023-01857-w","article-title":"Managing psoriatic arthritis patients presenting with axial symptoms","volume":"83","author":"Poddubnyy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jbspin.2023.105625_bib0525","doi-asserted-by":"crossref","first-page":"e002011","DOI":"10.1136\/rmdopen-2021-002011","article-title":"Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings","volume":"8","author":"Diaz","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105625_bib0530","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/AJR.04.1798","article-title":"Psoriatic arthritis and rheumatoid arthritis: findings in contrast-enhanced MRI","volume":"187","author":"Schoellnast","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0535","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","article-title":"Hla-B27","volume":"33","author":"Bowness","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0540","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/diagnostics13071342","article-title":"MRI findings in axial psoriatic spondylarthritis","volume":"13","author":"Pascu","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0545","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0550","first-page":"kead162","article-title":"Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort","author":"Baraliakos","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0555","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3899\/jrheum.220315","article-title":"Management of peripheral arthritis in patients with psoriatic arthritis: an updated literature review Informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Leung","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0560","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0565","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105625_bib0570","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105625_bib0575","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1093\/rheumatology\/keab285","article-title":"Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies","volume":"60","author":"McGonagle","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0580","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0585","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0590","first-page":"225","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study","volume":"81","author":"Kristensen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0595","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Ostor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0600","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","article-title":"Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase 2 randomized trial","volume":"9","author":"Mease","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2023.105625_bib0605","doi-asserted-by":"crossref","first-page":"e001149","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105625_bib0610","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0615","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2023.105625_bib0620","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jbspin.2023.105625_bib0625","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14712598.2022.2090834","article-title":"IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?","volume":"22","author":"Atzeni","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jbspin.2023.105625_bib0630","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/annrheumdis-2021-221422","article-title":"No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related \u201cphysician-reported spondylitis\u201d?","volume":"81","author":"Braun","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105625_bib0635","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/acr.20017","article-title":"Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis","volume":"62","author":"Fernandez-Sueiro","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2023.105625_bib0640","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","article-title":"Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial","volume":"23","author":"Gladman","year":"2022","journal-title":"Trials"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23001045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23001045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:29:38Z","timestamp":1761150578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X23001045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1297319X23001045"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105625","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105625"}}